Peter Jackson
Virginia Commonwealth University
16 Papers
5 Citations
Peter Jackson is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 3, co-authored 8 publications. Previous affiliations of Peter Jackson include Yale University & Oregon Health & Science University.
Chat about Author
Papers
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Marcia A Friedman,Brian Le,Janelle Stevens,Julianna Desmarais,Daniel R Seifer,Kimberly Ogle,Dongseok Choi,Christina A. Harrington,Peter Jackson,James T. Rosenbaum,James T. Rosenbaum +10 more
TL;DR: In this article, a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid-sparing therapy in corticosteroid-dependent pulmonary sarcoidosis was conducted.
Health Equity and Respiratory Diseases in Low- and Middle-Income Countries
TL;DR: This paper found that over 80% of the morbidity and mortality related to acute and chronic respiratory diseases occur in low and middle-income countries (LMICs), a reflection of vast disparities in care for these conditions.
9
The global significance of PRISm: how data from low- and middle-income countries link physiology to inflammation.
TL;DR: Does the high rate and unique risk factors of preserved ratio impaired spirometry in low- and middle-income countries have something to teach us about the physiology of this highly prevalent pattern?
8
Risk factors for disruptions in tuberculosis care in Uganda during the COVID-19 pandemic
Peter Jackson,Stella Zawedde Muyanja,I. Sekitoleko,M. Bbuye,R C Padalkar,Trishul Siddharthan +5 more
TL;DR: In this article , the authors examined patient level risk factors for disruption in TB care during the COVID-19 pandemic in Uganda and found that TB care disruption occurred in 57% (385/672) of patients.
Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial
Trishul Siddharthan,Trishul Siddharthan,Suzanne L. Pollard,Suzanne L. Pollard,Peter Jackson,Nicole M Robertson,Nicole M Robertson,Adaeze C. Wosu,Nihaal Rahman,Nihaal Rahman,Roma Padalkar,Roma Padalkar,Isaac Sekitoleko,Esther Namazzi,Patricia Alupo,John R. Hurst,Robert Kalyesubula,David W. Dowdy,Robert A. Wise,Robert A. Wise,Peter J. Barnes,William Checkley,William Checkley,Bruce Kirenga +23 more
TL;DR: The Low-dose Theophylline for the Management of Biomass-associated COPD (LODOT-BCOPD) trial as discussed by the authors investigates the clinical efficacy and cost-effectiveness of low-dose theophyllines for the management of biomass-related COPD in a low-and middle-income setting.